Oncodesign Precision Medicine Swings to H1 2026 Net Loss of EUR 2.04 Million

Bitget2026/10/22 16:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oncodesign Precision Medicine swung to a first-half 2026 net loss of EUR 2.04 million from a EUR 9.85 million year-earlier profit.
Revenue fell 21% to EUR 110,000 from a year earlier.
Consumed purchases dropped 52% to EUR 1.08 million, while personnel expenses declined 42% to EUR 870,000.
Cash totaled EUR 2.86 million at June 30; continued operations remain dependent on securing additional funding.
Michael J. Fox Foundation funding supports OPM-201 development toward a phase 1b Parkinson’s trial in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncodesign Precision Medicine SA published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oncodesign Precision Medicine Swings to H1 2026 Net Loss of EUR 2.04 Million

You may also like

Crypto prices